R P van Rij1, S Broersen, J Goudsmit, R A Coutinho, H Schuitemaker. 1. Department of Clinical Viro-Immunology, Central Laboratory of The Netherlands Red Cross Blood Transfusion Service, and University of Amsterdam, Academic Medical Centre.
Abstract
BACKGROUND: A G-to-A transition in the 3' untranslated region (UTR) of stromal cell-derived factor (SDF)-1 gene (SDF1-3'A) has recently been described, which in the homozygous state was associated with delayed disease progression. OBJECTIVE: To analyse the effect of the SDF-1 polymorphism on AIDS-free survival and survival after AIDS diagnosis, also in relation to viral phenotype. DESIGN: Retrospective longitudinal study among 344 homosexual HIV-1-infected men. RESULTS: A more rapid progression to AIDS (Centers for Disease Control and Prevention 1993 definition) was observed in SDF1-3'A/3'A subjects than in wild-type (SDF1-wt/wt) subjects (relative hazard, 1.75; P = 0.07). Using death as an endpoint, accelerated progression was no longer observed (relative hazard, 0.93; P = 0.84), suggesting a late protective effect of the SDF1-3'A/3'A genotype. Indeed, survival after AIDS diagnosis was significantly delayed in SDF1-3'A/3'A subjects (relative hazard, 0.40; P = 0.02). No effect of the SDF1-3'A/wt genotype on disease progression was observed. Interestingly, a higher frequency of Kaposi's sarcoma was observed as the AIDS-defining event among SDF1-3'A/3'A (40.0%) and SDF1-3'A/wt (30.6%) subjects than in SDF1-wt/wt subjects (17.0%). At the end of the study the total frequency of syncytium-inducing (SI) HIV-1 variants was lower in SDF1-3'A/3'A subjects (22.2%) than in SDF1-3'A/wt (32.5%) and SDF1-wt/wt subjects (40.5%), although not significantly. SDF-1 genotype did not influence the rate of evolution to SI HIV-1. Progression to AIDS after the emergence of SI HIV-1 was accelerated in SDF1-3'A/3'A subjects compared with the SDF1-wt/wt genotypic group (relative hazard, 4.04; P = 0.06). CONCLUSIONS: In our study group, homozygosity for a G-to-A transition in the 3' UTR of SDF-1 is associated with an accelerated progression to AIDS but a subsequent prolonged survival after AIDS diagnosis.
BACKGROUND: A G-to-A transition in the 3' untranslated region (UTR) of stromal cell-derived factor (SDF)-1 gene (SDF1-3'A) has recently been described, which in the homozygous state was associated with delayed disease progression. OBJECTIVE: To analyse the effect of the SDF-1 polymorphism on AIDS-free survival and survival after AIDS diagnosis, also in relation to viral phenotype. DESIGN: Retrospective longitudinal study among 344 homosexual HIV-1-infectedmen. RESULTS: A more rapid progression to AIDS (Centers for Disease Control and Prevention 1993 definition) was observed in SDF1-3'A/3'A subjects than in wild-type (SDF1-wt/wt) subjects (relative hazard, 1.75; P = 0.07). Using death as an endpoint, accelerated progression was no longer observed (relative hazard, 0.93; P = 0.84), suggesting a late protective effect of the SDF1-3'A/3'A genotype. Indeed, survival after AIDS diagnosis was significantly delayed in SDF1-3'A/3'A subjects (relative hazard, 0.40; P = 0.02). No effect of the SDF1-3'A/wt genotype on disease progression was observed. Interestingly, a higher frequency of Kaposi's sarcoma was observed as the AIDS-defining event among SDF1-3'A/3'A (40.0%) and SDF1-3'A/wt (30.6%) subjects than in SDF1-wt/wt subjects (17.0%). At the end of the study the total frequency of syncytium-inducing (SI) HIV-1 variants was lower in SDF1-3'A/3'A subjects (22.2%) than in SDF1-3'A/wt (32.5%) and SDF1-wt/wt subjects (40.5%), although not significantly. SDF-1 genotype did not influence the rate of evolution to SI HIV-1. Progression to AIDS after the emergence of SI HIV-1 was accelerated in SDF1-3'A/3'A subjects compared with the SDF1-wt/wt genotypic group (relative hazard, 4.04; P = 0.06). CONCLUSIONS: In our study group, homozygosity for a G-to-A transition in the 3' UTR of SDF-1 is associated with an accelerated progression to AIDS but a subsequent prolonged survival after AIDS diagnosis.
Authors: Jianming Tang; Brent Shelton; Nina J Makhatadze; Yuting Zhang; Margaret Schaen; Leslie G Louie; James J Goedert; Eric C Seaberg; Joseph B Margolick; John Mellors; Richard A Kaslow Journal: J Virol Date: 2002-01 Impact factor: 5.103
Authors: G C John; C Rousseau; T Dong; S Rowland-Jones; R Nduati; D Mbori-Ngacha; T Rostron; J K Kreiss; B A Richardson; J Overbaugh Journal: J Virol Date: 2000-06 Impact factor: 5.103
Authors: E E Nakayama; Y Hoshino; X Xin; H Liu; M Goto; N Watanabe; H Taguchi; A Hitani; A Kawana-Tachikawa; M Fukushima; K Yamada; W Sugiura; S I Oka; A Ajisawa; H Sato; Y Takebe; T Nakamura; Y Nagai; A Iwamoto; T Shioda Journal: J Virol Date: 2000-06 Impact factor: 5.103
Authors: T Shioda; E E Nakayama; Y Tanaka; X Xin; H Liu; A Kawana-Tachikawa; A Kato; Y Sakai; Y Nagai; A Iwamoto Journal: J Virol Date: 2001-04 Impact factor: 5.103
Authors: H Liu; D Chao; E E Nakayama; H Taguchi; M Goto; X Xin; J K Takamatsu; H Saito; Y Ishikawa; T Akaza; T Juji; Y Takebe; T Ohishi; K Fukutake; Y Maruyama; S Yashiki; S Sonoda; T Nakamura; Y Nagai; A Iwamoto; T Shioda Journal: Proc Natl Acad Sci U S A Date: 1999-04-13 Impact factor: 11.205
Authors: Desiree C Petersen; Richard H Glashoff; Sadeep Shrestha; Julie Bergeron; Annette Laten; Bert Gold; Estrelita Janse van Rensburg; Michael Dean; Vanessa M Hayes Journal: J Acquir Immune Defic Syndr Date: 2005-12-15 Impact factor: 3.731